Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis

Pediatric Pulmonology

Volumn 27, Issue 1, 1999, Pages 43-53

  Hordvik, Nancy L ^a   Sammut, Paul H ^a   Judy, C Gerald ^a   Colombo, John L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bronchodilators; Cystic fibrosis; Randomized controlled trial; Salmeterol

Indexed keywords

SALBUTAMOL; SALMETEROL;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; PRIORITY JOURNAL; SPIROMETRY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GENOTYPE; HOSPITALIZATION; HUMANS; MALE; PULMONARY VENTILATION; SPIROMETRY; TREATMENT OUTCOME;

EID: 0032947760     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199901)27:1<43::AID-PPUL9>3.0.CO;2-E     Document Type: Article

References (29)

1. Hordvik NL, Sammut PH, Judy CG, Colombo JL. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1996;154:156-160.
2. American Throracic Society. Statement on the Snowbird Workshop on Standardization of Spirometry. Am Rev Respir Dis 1979; 119:831-838.
3. Taussig LM, Kattwinkel J, Friedewald WI, Di Sant' Agnese PA. A new prognostic score and clinical evaluation system for cystic fibrosis. J Pediatr 1979;82:380-390.
4. Hamosh A, Corey M, Consortium Members. Cystic fibrosis genotype/phenotype consortium: correlation between genotype and phenotype in cystic fibrosis. N Engl J Med 1994;329:1308-1313.
5. Hamosh A, King TM, Rosenstein BJ, Corey M, Levison H, Consortium Members. Cystic fibrosis patients bearing the common missense mutation Gly Asp at codon 551 and the delta F508 are indistinguishable from delta F508 homozygotes except for decreased risk of meconium ileus. Am J Hum Genet 1992;51:245-250.
6. Drumm ML, Kelly TJ. Inhibition of specific phosphodiesterases in CF airway epithelial cells activates mutant CFTRs. Pediatr Pulmonol [Suppl 12] 1995;150.
7. Drumm ML, Wilkinson DJ, Smit LS, Worrel RT, Strong TV, Frizzel RA, Dawson DC, Collins FS. Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 1991;254:1797-1799.
8. Sheppard DN, Rich DP, Ostegaard LS, Gregory RJ, Smith AE, Welsh M. Mutations in CFTR associated with mild disease form chloride channels with altered pore properties. Nature 1993;362: 160-164.
9. Becq F, Jensen TJ, Chang XB, Jensen TJ, Chang X, Savoia A, Rommens J, Tsui L, Buchwald M, Rordan J, Hanrahan J. Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc Natl Acad Sci USA 1994;91:9160-9164.
10. Snedecor GW, Cochran WG, editors. Statistical methods, 6th ed. Ames, IA: Iowa State University Press; 1967.
11. Shapiro GG, Bamman J, Kanarek P, Bierman W. The paradoxical effect of adrenergic and methylxanthine drugs in cystic fibrosis. Pediatrics 1976;58:740-743.
12. Zach MS, Oberwalder B, Forche F, Polgar G. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis 1985;131:537-543.
13. Eber EB, Oberwalder B, Zach M. Airway obstruction and airway instability in cystic fibrosis; the isolated and combined effects of theophylline and sympathomimetics. Pediatr Pulmonol 1988;4: 205-212.
14. Landau LI, Phelan PD. The variable effect of a bronchodilating agent on pulmonary function in cystic fibrosis. J Pediatr 1973;82: 863-868.
15. Kattan MA, Mansell A, Levison H, Corey M, Krastins IRB. Response to aerosol salbutamol, sch 1000, and placebo in cystic fibrosis. Thorax 1980;35:531-535.
16. Zinman R, Wohl MEB, Ingram RH. Nonhomogeneous lung emptying in cystic fibrosis patients: volume history and bronchodilator effects. Am Rev Respir Dis 1991;143:1257-1261.
17. Hordvik NL, Konig P, Morris D, Kreutz C, Barberro GJ. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis 1985;131:889-893.
18. Pattishall EN. Longitudinal response of pulmonary function to bronchodilators in cystic fibrosis. Pediatr Pulmonol 1990;9:80-85.
19. Weintraub SJ, Eschenbacher WL. The inhaled bronchodilators. ipratropium bromide and metaproterenol in adults with CF. Chest 1989;95:861-864.
20. Pryor JA, Webber BA, Hodson ME, Batten JC. Evaluation of the forced expiration as an adjunct to postural drainage in treatment of cystic fibrosis. Br Med J [Clin Res] 1979;2:417-418.
21. Webber BA, Hofmeyr JL, Morgan MDL, Hodson ME. Effects of postural drainage, incorporating the forced expiration technique, on pulmonary function of cystic fibrosis. Br J Dis Chest 1986;80: 353-359.
22. Nickerson BG, Lemen RJ, Gerdes CB, Wegmann MJ, Robertson G. Within-subject variability and percent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 1980;122:859-866.
23. Desmond KJ, Demizio DL, Allen PD, MacDonald NE, Coates AL. Effect of salbutamol on gas compression in cystic fibrosis and asthma. Am J Respir Crit Care Med 1994;149:673-677.
24. Sanchez I, DeKoster J, Holbrow J, Chernick V. The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. Chest 1993;104:842-846.
25. van Haren EHJ, Lammers J-W, Lammers J, Feston J. van Herwaarden CLA. Bronchodilator response in adult patients with cystic fibrosis: effects on large and small airways. Eur Respir J 1991; 4:301-307.
26. Veil K, Bargon J, Dauletbaev N, Wiewrodt R, Buhl R. Effects of salmeterol on adult cystic fibrosis patients. Respir Crit Care Med 1997;155:638.
27. König P, Gayer D, Barberro GJ, Shaffer J. Short-term and long-term effects of albuterol in patients with cystic fibrosis: a preliminary report. Pediatr Pulmonol 1995;20:205-214.
28. Maconochie JG, Forster JK. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol 1992; 33:342-345.
29. Ward JK, Mann CY, Horton J, Ventresca GP. Systemic dynamic responses to oral doses of salmeterol in healthy subjects - Effects of activated charcoal. Am J Respir Crit Care Med [Suppl] 1997; 155:346.